EZH2 and ovarian serous adenocarcinoma: Six of seven candidates selected forimmunohistochemical validation were expressed in serous ovarian cancer,inclusion cysts, ovarian surface epithelium and in fallopian tube epithelium.Most were overexpressed in ovarian cancer compared with ovarian surfaceepithelium and/or inclusion cysts (EpCAM, EZH2, BIRC5) although BIRC5 and EZH2were expressed as highly in fallopian tube epithelium as in ovarian cancer.